News stories about MabVax Therapeutics Holdings (NASDAQ:MBVX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. MabVax Therapeutics Holdings earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.4841105448531 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
MabVax Therapeutics Holdings (NASDAQ:MBVX) traded up 1.43% during mid-day trading on Thursday, hitting $0.71. 312,295 shares of the stock traded hands. The company has a 50 day moving average of $0.68 and a 200-day moving average of $1.16. MabVax Therapeutics Holdings has a 12-month low of $0.43 and a 12-month high of $4.50. The stock’s market cap is $7.50 million.
MabVax Therapeutics Holdings (NASDAQ:MBVX) last posted its quarterly earnings results on Monday, August 14th. The company reported ($1.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.78). Equities research analysts forecast that MabVax Therapeutics Holdings will post ($2.91) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact MabVax Therapeutics Holdings (MBVX) Stock Price” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2017/10/26/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-mabvax-therapeutics-holdings-mbvx-stock-price.html.
About MabVax Therapeutics Holdings
MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.
Receive News & Ratings for MabVax Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.